Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Diaz

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
NPJ Precision Oncology|October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
Biomedicines|August 26, 2022
ALCAM: A Novel Surface Marker on EpCAM<sup>low</sup> Circulating Tumor CellsRossana Signorelli, Teresa Maidana Giret, Oliver Umland, et al.
Cell Cycle (Georgetown, Tex.)|October 14, 2009
microRNAs regulate human embryonic stem cell divisionJunlin Qi, Jenn-Yah Yu, Halyna R Shcherbata, et al.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
British Journal of Cancer|October 12, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas J A Adamson, et al.
Cancer Medicine|July 18, 2022
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 studyAnna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsAlessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
NPJ Precision Oncology|October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
Biomedicines|August 26, 2022
ALCAM: A Novel Surface Marker on EpCAM<sup>low</sup> Circulating Tumor CellsRossana Signorelli, Teresa Maidana Giret, Oliver Umland, et al.
Cell Cycle (Georgetown, Tex.)|October 14, 2009
microRNAs regulate human embryonic stem cell divisionJunlin Qi, Jenn-Yah Yu, Halyna R Shcherbata, et al.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
British Journal of Cancer|October 12, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas J A Adamson, et al.
Cancer Medicine|July 18, 2022
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 studyAnna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
The Lancet. Oncology|May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialAlessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma GroupsAlessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 4